The idiopathic inflammatory myopathy (IIM) landscape is evolving rapidly, transforming how clinicians recognize disease, assess risk, and select treatment, but translating these advances into everyday practice remains a challenge. As biomarkers and myositis-specific autoantibodies enable increasingly precise subtype classification, clinicians need practical strategies to move beyond a one-size-fits-all approach to “myositis”, confidently distinguish IIM subtypes from key mimics, and determine when negative, incomplete, or discordant serology should prompt further diagnostic evaluation rather than premature diagnostic closure. Accurate classification must also translate into identifying patients at risk for serious complications such as interstitial lung disease (ILD), malignancy, and dysphagia. At the same time, persistent glucocorticoid exposure and a rapidly evolving treatment evidence base make it essential for clinicians to understand current steroid-sparing options, distinguish approved and investigational approaches, and appropriately interpret the clinical rationale and emerging evidence for neonatal Fc receptor (FcRn) inhibition. Education is needed to equip neurologists, neuromuscular specialists, rheumatologists, dermatologists, pulmonologists, primary care physicians (PCPs), advanced practice providers, pharmacists, nurses, rehabilitation professionals, speech-language pathologists (SLPs), and other members of the interprofessional care team with actionable strategies for earlier recognition, targeted comorbidity assessment, and personalized treatment that addresses outcomes and quality-of-life priorities that matter most to patients.
In this case-based CME Outfitters live webcast, expert faculty will guide learners through real-world diagnostic and treatment decision points that translate biomarker-informed IIM classification into clinical practice, linking subtype recognition to further diagnostic evaluation, targeted comorbidity assessment, multidisciplinary care, and current and emerging steroid-sparing treatment strategies. Patient perspectives on function, treatment burden, quality of life, and personal goals will be integrated into these decisions, while investigational FcRn inhibition is considered within a fair and balanced therapeutic landscape.
